Signs of life

The UK insurer seems to have tried and failed to do a $3bn deal with a US peer. But a rising share price will help it fund alternative buys. That s no bad thing. Aviva needs to diversify away from its lowgrowth home market and has a solid M&A record as both buyer and seller.